DGI:Knochen-, Gelenks- und Protheseninfektionen/Hämatogene Osteomyelitis/Therapie/Erregerspezifische Therapie: Difference between revisions
imported>Fuhrmanns No edit summary |
imported>Brinkery No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 7: | Line 7: | ||
Auch bei der hämatogenen Osteomyelitis kann die chirurgische Intervention hilfreich sein, z.B. zur Entfernung von Nekrosen oder Knochensequestern. Deswegen hier immer chirurgisches Konsil anfragen (Orthopädie oder Unfallchirurgie). | Auch bei der hämatogenen Osteomyelitis kann die chirurgische Intervention hilfreich sein, z.B. zur Entfernung von Nekrosen oder Knochensequestern. Deswegen hier immer chirurgisches Konsil anfragen (Orthopädie oder Unfallchirurgie). | ||
{| class="wikitable sortable mw-collapsible MsoTableGrid jquery-tablesorter" border="1" cellspacing="0" cellpadding="0" width="888" style="box-sizing: inherit; border-collapse: collapse; border-spacing: 0px; background-color: rgb(248, 249, 250); font-size: 14px; color: rgb(34, 34, 34); margin: 1em 0px; border: none; font-family: "Open Sans", Roboto, arial, sans-serif; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;" | |||
| style="width:113.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="151" valign="top" |<span style="box-sizing: inherit; font-size: 9pt;">'''Erreger'''</span> | |||
| style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |<span style="box-sizing: inherit; font-size: 9pt;">'''Präferenz'''</span> | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |<span style="box-sizing: inherit; font-size: 9pt;">'''Substanz'''</span> | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |<span style="box-sizing: inherit; font-size: 9pt;">'''Dosierung'''</span> | |||
| style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" |<span class="mw-collapsible-toggle mw-collapsible-toggle-default" role="button" tabindex="0" style="box-sizing: inherit; cursor: pointer; float: right; user-select: none;">Einklappen</span><span style="box-sizing: inherit; font-size: 9pt;">'''Kommentar'''</span> | |||
|- style="box-sizing: inherit;" | |||
| rowspan="13" style="width:113.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="151" valign="top" |''Staphylococcus aureus'' | |||
und andere Staphylokokken, | |||
Oxacillin-sensibel | |||
| rowspan="2" style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |Intravenöse Initialtherapie | |||
1. Wahl | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |Flucloxacillin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |6 x 2 g i.v. | |||
| rowspan="2" style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" | | |||
|- style="box-sizing: inherit;" | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |oder | |||
Cefazolin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |3 x 2 g i.v. | |||
|- style="box-sizing: inherit;" | |||
| rowspan="2" style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |Alternative bei schwerer Allergie | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |Vancomycin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |* | |||
| rowspan="2" style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" |*[[:Datei:DGI:Infoblatt Vancomycin RGU.pdf]] | |||
<nowiki>**</nowiki> hohe Dosis off-label, Expertenmeinung | |||
|- style="box-sizing: inherit;" | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |oder | |||
Daptomycin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |1 x 8 – 10** mg/kg i.v. | |||
|- style="box-sizing: inherit;" | |||
| rowspan="2" style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |bei Fremdmaterial-assoziierter Infektion | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |<span style="box-sizing: inherit;">plus</span> | |||
<span style="box-sizing: inherit;">Rifampicin</span> | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |1 x 600 mg i.v. bzw. | |||
2 x 450 mg p.o. | |||
| style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" |wegen sehr guter Bioverfügbarkeit orale Gabe bevorzugen | |||
|- style="box-sizing: inherit;" | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |alternativ | |||
plus | |||
Fosfomycin <span style="box-sizing: inherit;"> </span> | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |3 x 5 g i.v. | |||
| style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" | | |||
|- style="box-sizing: inherit;" | |||
| rowspan="4" style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |Orale Anschlusstherapie | |||
''ohne'' Fremdmaterial | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |Cotrimoxazol | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |3 x 960 mg p.o | |||
| rowspan="4" style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" |'''Cave:''' wegen schlechter Bioverfügbarkeit orale Betalaktame meiden. | |||
|- style="box-sizing: inherit;" | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |oder | |||
Clindamycin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |3 x 600 mg p.o | |||
|- style="box-sizing: inherit;" | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |oder | |||
Doxycyclin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |2 x 100 mg p.o. | |||
|- style="box-sizing: inherit;" | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |oder | |||
Levofloxacin | |||
plus | |||
Rifampicin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |2 x 500 mg p.o. | |||
plus | |||
2 x 450 mg p.o. | |||
|- style="box-sizing: inherit;" | |||
| rowspan="3" style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |Orale Anschlusstherapie | |||
bei ''Fremdmaterial''-assoziierter Infektion | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |Cotrimoxazol | |||
plus | |||
Rifampicin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |3 x 960 mg p.o. | |||
plus | |||
2 x 450 mg p.o. | |||
| rowspan="3" style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" |möglichst keine Kombination von Rifampicin mit Clindamycin oder Linezolid | |||
|- style="box-sizing: inherit;" | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |oder | |||
Doxycyclin | |||
plus | |||
Rifampicin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |2 x 100 mg p.o. | |||
plus | |||
2 x 450 mg p.o. | |||
|- style="box-sizing: inherit;" | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |oder | |||
Levofloxacin | |||
plus | |||
Rifampicin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |2 x 500 mg p.o. | |||
plus | |||
2 x 450 mg p.o. | |||
|- style="box-sizing: inherit;" | |||
| rowspan="5" style="width:113.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="151" valign="top" |''Staphylococcus aureus'' | |||
und andere Staphylokokken, | |||
Oxacillin-resistent | |||
| rowspan="2" style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |Intravenöse Initialtherapie | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |Vancomycin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |* | |||
| rowspan="2" style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" |*[[:Datei:DGI:Infoblatt Vancomycin RGU.pdf]] | |||
<nowiki>**</nowiki> hohe Dosis off-label, Expertenmeinung | |||
|- style="box-sizing: inherit;" | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |oder | |||
Daptomycin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |1 x 8 – 10** mg/kg i.v. | |||
|- style="box-sizing: inherit;" | |||
| rowspan="2" style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |bei ''Fremdmaterial''-assoziierter Infektion | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |<span style="box-sizing: inherit;">plus</span> | |||
<span style="box-sizing: inherit;">Rifampicin</span> | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |1 x 600 mg i.v. bzw. | |||
2 x 450 mg p.o. | |||
| style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" |wegen sehr guter Bioverfügbarkeit orale Gabe bevorzugen | |||
|- style="box-sizing: inherit;" | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |alternativ | |||
plus | |||
Fosfomycin <span style="box-sizing: inherit;"> </span> | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |3 x 5 g i.v. | |||
| style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" | | |||
|- style="box-sizing: inherit;" | |||
| style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |Orale Anschlusstherapie | |||
| colspan="3" style="width:432.35pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="576" valign="top" |s.oben | |||
|- style="box-sizing: inherit;" | |||
| rowspan="4" style="width:113.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="151" valign="top" |''Enterococcus'' spp., | |||
Ampicillin-sensibel | |||
| style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |Intravenöse Initialtherapie | |||
1.Wahl | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |Ampicillin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |6 x 2 g i.v. | |||
| style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" | | |||
|- style="box-sizing: inherit;" | |||
| rowspan="2" style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |Alternativen | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |Vancomycin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |'''*''' | |||
| style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" |*[[:Datei:DGI:Infoblatt Vancomycin RGU.pdf]] | |||
|- style="box-sizing: inherit;" | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |oder | |||
Daptomycin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |1 x 10 - 12 mg/kg <span class="mw-lingo-term" data-lingo-term-id="56d721ccadb8bbfd8b47390d82a6ea4b" data-hasqtip="0" style="box-sizing: inherit; border-bottom: 1px dotted rgb(187, 187, 255); cursor: default;"><span class="mw-lingo-term" data-lingo-term-id="56d721ccadb8bbfd8b47390d82a6ea4b" data-hasqtip="1" style="box-sizing: inherit; border-bottom: 1px dotted rgb(187, 187, 255); cursor: default;"><span class="mw-lingo-term" data-lingo-term-id="56d721ccadb8bbfd8b47390d82a6ea4b" data-hasqtip="2" style="box-sizing: inherit; border-bottom: 1px dotted rgb(187, 187, 255); cursor: default;">KG</span></span></span> i.v. | |||
| style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" |hohe Dosis off-label, Expertenmeinung | |||
|- style="box-sizing: inherit;" | |||
| style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |Orale Anschlusstherapie | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |Amoxicillin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |3 x 1 g p.o. | |||
| style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" | | |||
|- style="box-sizing: inherit;" | |||
| rowspan="3" style="width:113.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="151" valign="top" |''Enterococcus'' spp., | |||
Ampicillin-resistent | |||
| rowspan="2" style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |Intravenöse Initialtherapie | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |Vancomycin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |'''*''' | |||
| style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" |*[[:Datei:DGI:Infoblatt Vancomycin RGU.pdf]] | |||
|- style="box-sizing: inherit;" | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |oder | |||
Daptomycin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |1 x 10 - 12 mg/kg <span class="mw-lingo-term" data-lingo-term-id="56d721ccadb8bbfd8b47390d82a6ea4b" data-hasqtip="3" style="box-sizing: inherit; border-bottom: 1px dotted rgb(187, 187, 255); cursor: default;"><span class="mw-lingo-term" data-lingo-term-id="56d721ccadb8bbfd8b47390d82a6ea4b" data-hasqtip="4" style="box-sizing: inherit; border-bottom: 1px dotted rgb(187, 187, 255); cursor: default;"><span class="mw-lingo-term" data-lingo-term-id="56d721ccadb8bbfd8b47390d82a6ea4b" data-hasqtip="5" style="box-sizing: inherit; border-bottom: 1px dotted rgb(187, 187, 255); cursor: default;">KG</span></span></span> i.v. | |||
| style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" |hohe Dosis off-label, Expertenmeinung | |||
|- style="box-sizing: inherit;" | |||
| style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |Orale Anschlusstherapie | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |Linezolid | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |2 x 600 mg p.o. | |||
| style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" |Linezolid max. 28 Tage zugelassen | |||
|- style="box-sizing: inherit;" | |||
| rowspan="2" style="width:113.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="151" valign="top" |Streptokokken | |||
| style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |Intravenöse Initialtherapie | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |Benzylpenicillin (Penicillin G) | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |<span style="box-sizing: inherit;">4 x 5 Mio I.E. i.v. </span> | |||
| style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" | | |||
|- style="box-sizing: inherit;" | |||
| style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |Orale Anschlusstherapie | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |Amoxicillin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |<span style="box-sizing: inherit;">3 x 1 g p.o.</span> | |||
| style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" | | |||
|- style="box-sizing: inherit;" | |||
| rowspan="3" style="width:113.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="151" valign="top" |Enterobakterien | |||
| rowspan="2" style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |Intravenöse Initialtherapie | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |Ampicillin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |6 x 2 g i.v. | |||
| rowspan="2" style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" | | |||
|- style="box-sizing: inherit;" | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |Ceftriaxon | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |1 x 2 g i.v. | |||
|- style="box-sizing: inherit;" | |||
| style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |Orale Anschlusstherapie | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |Ciprofloxacin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |2 x 750 mg p.o | |||
| style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" | | |||
|- style="box-sizing: inherit;" | |||
| rowspan="3" style="width:113.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="151" valign="top" |''Pseudomonas aeruginosa'' | |||
| rowspan="2" style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |Intravenöse Initialtherapie | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |Piperacillin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |4 x 4 g i.v. | |||
| rowspan="2" style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" |Bei Pseudomonas-Infektionen immer hohe Dosis verwenden. | |||
|- style="box-sizing: inherit;" | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |oder | |||
Ceftazidim | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |3 x 2 g i.v. | |||
|- style="box-sizing: inherit;" | |||
| style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |Orale Anschlusstherapie | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |Ciprofloxacin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |2 x 750 mg p.o. | |||
| style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" | | |||
|- style="box-sizing: inherit;" | |||
| rowspan="2" style="width:113.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="151" valign="top" |''Candida'' spp. | |||
''<span style="box-sizing: inherit;">''' '''</span>'' | |||
| style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |Intravenöse Initialtherapie | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |Caspofungin | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |Tag 1: <span style="box-sizing: inherit;"> </span> | |||
1 x 70 mg i.v., | |||
danach: 1 x 50 mg i.v. <span style="box-sizing: inherit;"> <span style="box-sizing: inherit;"> </span></span><span class="mw-lingo-term" data-lingo-term-id="56d721ccadb8bbfd8b47390d82a6ea4b" data-hasqtip="6" style="box-sizing: inherit; border-bottom: 1px dotted rgb(187, 187, 255); cursor: default;"><span class="mw-lingo-term" data-lingo-term-id="56d721ccadb8bbfd8b47390d82a6ea4b" data-hasqtip="7" style="box-sizing: inherit; border-bottom: 1px dotted rgb(187, 187, 255); cursor: default;"><span class="mw-lingo-term" data-lingo-term-id="56d721ccadb8bbfd8b47390d82a6ea4b" data-hasqtip="8" style="box-sizing: inherit; border-bottom: 1px dotted rgb(187, 187, 255); cursor: default;">KG</span></span></span> ≤ 80 kg | |||
bzw. 1 x 70 mg i.v. <span style="box-sizing: inherit;"> </span> <span class="mw-lingo-term" data-lingo-term-id="56d721ccadb8bbfd8b47390d82a6ea4b" data-hasqtip="9" style="box-sizing: inherit; border-bottom: 1px dotted rgb(187, 187, 255); cursor: default;"><span class="mw-lingo-term" data-lingo-term-id="56d721ccadb8bbfd8b47390d82a6ea4b" data-hasqtip="10" style="box-sizing: inherit; border-bottom: 1px dotted rgb(187, 187, 255); cursor: default;"><span class="mw-lingo-term" data-lingo-term-id="56d721ccadb8bbfd8b47390d82a6ea4b" data-hasqtip="11" style="box-sizing: inherit; border-bottom: 1px dotted rgb(187, 187, 255); cursor: default;">KG</span></span></span> > 80 kg | |||
| style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" | | |||
|- style="box-sizing: inherit;" | |||
| style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |Orale Anschlusstherapie | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |Fluconazol | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |<span style="box-sizing: inherit;">Einmalig 1 x 800 mg p.o.,</span> | |||
<span style="box-sizing: inherit;">weiter mit 1 x 400 mg p.o.</span> | |||
| style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" | | |||
|- style="box-sizing: inherit;" | |||
| rowspan="2" style="width:113.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="151" valign="top" |''Mycobacterium tuberculosis'' | |||
| style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |Initialtherapie 2 Monate | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |<span style="box-sizing: inherit;">Isoniazid (in Kombi mit Pyridoxin)</span> | |||
plus Rifampicin plus Pyrazinamid plus Ethambutol | |||
| style="width:5cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="189" valign="top" |s. Dosierungsempfehlung Link Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose | |||
| rowspan="2" style="width:7cm;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="265" valign="top" | | |||
|- style="box-sizing: inherit;" | |||
| style="width:120.5pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="161" valign="top" |Anschlusstherapie | |||
| style="width:92.15pt;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" width="123" valign="top" |<span style="box-sizing: inherit;">Isoniazid (in Kombi mit Pyridoxin)</span> | |||
<span style="box-sizing: inherit;">plus R</span>ifampicin | |||
|} | |||
Latest revision as of 10:21, 31 March 2022
Siehe Tabelle am Ende des Kapitels.
Die Therapiedauer bei der hämatogenen Osteomyelitis wird generell mit 6 Wochen angegeben. Je nach klinischem und radiologischem Verlauf kann auch eine längere Therapiedauer notwendig sein.
Grundsätzlich ist eine Oralisierung der Therapie nach 1 – 2 Wochen möglich. Wichtig hierfür ist, dass es eine wirksame Substanz mit guter Bioverfügbarkeit nach oraler Einnahme gibt und dass die orale Aufnahme und die Compliance gewährleistet sind.
Auch bei der hämatogenen Osteomyelitis kann die chirurgische Intervention hilfreich sein, z.B. zur Entfernung von Nekrosen oder Knochensequestern. Deswegen hier immer chirurgisches Konsil anfragen (Orthopädie oder Unfallchirurgie).
| Erreger | Präferenz | Substanz | Dosierung | EinklappenKommentar |
| Staphylococcus aureus
und andere Staphylokokken, Oxacillin-sensibel |
Intravenöse Initialtherapie
1. Wahl |
Flucloxacillin | 6 x 2 g i.v. | |
| oder
Cefazolin |
3 x 2 g i.v. | |||
| Alternative bei schwerer Allergie | Vancomycin | * | *Datei:DGI:Infoblatt Vancomycin RGU.pdf
** hohe Dosis off-label, Expertenmeinung | |
| oder
Daptomycin |
1 x 8 – 10** mg/kg i.v. | |||
| bei Fremdmaterial-assoziierter Infektion | plus
Rifampicin |
1 x 600 mg i.v. bzw.
2 x 450 mg p.o. |
wegen sehr guter Bioverfügbarkeit orale Gabe bevorzugen | |
| alternativ
plus Fosfomycin |
3 x 5 g i.v. | |||
| Orale Anschlusstherapie
ohne Fremdmaterial |
Cotrimoxazol | 3 x 960 mg p.o | Cave: wegen schlechter Bioverfügbarkeit orale Betalaktame meiden. | |
| oder
Clindamycin |
3 x 600 mg p.o | |||
| oder
Doxycyclin |
2 x 100 mg p.o. | |||
| oder
Levofloxacin plus Rifampicin |
2 x 500 mg p.o.
plus 2 x 450 mg p.o. | |||
| Orale Anschlusstherapie
bei Fremdmaterial-assoziierter Infektion |
Cotrimoxazol
plus Rifampicin |
3 x 960 mg p.o.
plus 2 x 450 mg p.o. |
möglichst keine Kombination von Rifampicin mit Clindamycin oder Linezolid | |
| oder
Doxycyclin plus Rifampicin |
2 x 100 mg p.o.
plus 2 x 450 mg p.o. | |||
| oder
Levofloxacin plus Rifampicin |
2 x 500 mg p.o.
plus 2 x 450 mg p.o. | |||
| Staphylococcus aureus
und andere Staphylokokken, Oxacillin-resistent |
Intravenöse Initialtherapie | Vancomycin | * | *Datei:DGI:Infoblatt Vancomycin RGU.pdf
** hohe Dosis off-label, Expertenmeinung |
| oder
Daptomycin |
1 x 8 – 10** mg/kg i.v. | |||
| bei Fremdmaterial-assoziierter Infektion | plus
Rifampicin |
1 x 600 mg i.v. bzw.
2 x 450 mg p.o. |
wegen sehr guter Bioverfügbarkeit orale Gabe bevorzugen | |
| alternativ
plus Fosfomycin |
3 x 5 g i.v. | |||
| Orale Anschlusstherapie | s.oben | |||
| Enterococcus spp.,
Ampicillin-sensibel |
Intravenöse Initialtherapie
1.Wahl |
Ampicillin | 6 x 2 g i.v. | |
| Alternativen | Vancomycin | * | *Datei:DGI:Infoblatt Vancomycin RGU.pdf | |
| oder
Daptomycin |
1 x 10 - 12 mg/kg KG i.v. | hohe Dosis off-label, Expertenmeinung | ||
| Orale Anschlusstherapie | Amoxicillin | 3 x 1 g p.o. | ||
| Enterococcus spp.,
Ampicillin-resistent |
Intravenöse Initialtherapie | Vancomycin | * | *Datei:DGI:Infoblatt Vancomycin RGU.pdf |
| oder
Daptomycin |
1 x 10 - 12 mg/kg KG i.v. | hohe Dosis off-label, Expertenmeinung | ||
| Orale Anschlusstherapie | Linezolid | 2 x 600 mg p.o. | Linezolid max. 28 Tage zugelassen | |
| Streptokokken | Intravenöse Initialtherapie | Benzylpenicillin (Penicillin G) | 4 x 5 Mio I.E. i.v. | |
| Orale Anschlusstherapie | Amoxicillin | 3 x 1 g p.o. | ||
| Enterobakterien | Intravenöse Initialtherapie | Ampicillin | 6 x 2 g i.v. | |
| Ceftriaxon | 1 x 2 g i.v. | |||
| Orale Anschlusstherapie | Ciprofloxacin | 2 x 750 mg p.o | ||
| Pseudomonas aeruginosa | Intravenöse Initialtherapie | Piperacillin | 4 x 4 g i.v. | Bei Pseudomonas-Infektionen immer hohe Dosis verwenden. |
| oder
Ceftazidim |
3 x 2 g i.v. | |||
| Orale Anschlusstherapie | Ciprofloxacin | 2 x 750 mg p.o. | ||
| Candida spp.
|
Intravenöse Initialtherapie | Caspofungin | Tag 1:
1 x 70 mg i.v., danach: 1 x 50 mg i.v. KG ≤ 80 kg bzw. 1 x 70 mg i.v. KG > 80 kg |
|
| Orale Anschlusstherapie | Fluconazol | Einmalig 1 x 800 mg p.o.,
weiter mit 1 x 400 mg p.o. |
||
| Mycobacterium tuberculosis | Initialtherapie 2 Monate | Isoniazid (in Kombi mit Pyridoxin)
plus Rifampicin plus Pyrazinamid plus Ethambutol |
s. Dosierungsempfehlung Link Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose | |
| Anschlusstherapie | Isoniazid (in Kombi mit Pyridoxin)
plus Rifampicin | |||